A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Phase of Trial: Phase II
Latest Information Update: 04 May 2017
At a glance
- Drugs CJM 112 (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Sponsors Novartis
- 13 Dec 2016 Status changed from active, no longer recruiting to completed.
- 06 Nov 2016 This trial was completed in Denmark.
- 24 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.